Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin

被引:10
作者
Stewart, BA
Johnson, AP
Woodford, N
机构
[1] Royal Hosp NHS Trust, Microbiol & Virol Clin Grp, London E1 1BB, England
[2] Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England
关键词
D O I
10.1099/00222615-48-12-1103
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The mechanisms of resistance to ciprofloxacin and grepafloxacin were studied in 54 clinical isolates of Streptococcus pneumoniae. Restriction fragment length polymorphism analysis following HinfI digestion was used with DNA sequencing to identify mutations in the quinolone resistance-determining regions (QRDRs) of the parC and gyrA genes. Ciprofloxacin MICs up to 16 mg/L were not associated with mutations to these genes in approximately half of the isolates. In other isolates, moderate levels of ciprofloxacin resistance (MIC 8-16 mg/L) were associated with an alteration of ParC, most commonly entailing replacement of serine-79 by phenylalanine. High-level ciprofloxacin resistance (MIC 32-128 mg/L) entailed the additional mutation of GyrA with substitution of serine-83 by phenylalanine. Grepafloxacin MICs >4 mg/L were associated with this GyrA mutation alone; no relationship was detected between grepafloxacin MICs and mutation of the QRDR of parC.
引用
收藏
页码:1103 / 1106
页数:4
相关论文
共 11 条
[1]  
BERNARD L, 1994, CLIN MICROBIOL INFEC, V1, P60
[2]   The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin [J].
Brenwald, NP ;
Gill, MJ ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :458-460
[3]  
Eliopoulos G M, 1995, Drugs, V49 Suppl 2, P48
[4]  
GOLDSMITH CE, 1997, J ANTIMICROB CHEM SA, V40, pS11
[5]   In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections [J].
HoogkampKorstanje, JAA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :427-431
[6]   High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA [J].
Janoir, C ;
Zeller, V ;
Kitzis, MD ;
Moreau, NJ ;
Gutmann, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2760-2764
[7]   Activity of grepafloxacin against respiratory isolates of Streptococcus pneumoniae [J].
Johnson, AP ;
Warner, M ;
Parsons, T .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1997, 16 (08) :622-623
[8]   ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype [J].
Munoz, R ;
DelaCampa, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2252-2257
[9]   Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones [J].
Pan, XS ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :471-474
[10]   Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae [J].
Pan, XS ;
Ambler, J ;
Mehtar, S ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2321-2326